Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Tissue Engineering Co has a Cash Ratio of 5.80. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Japan Tissue Engineering Co's Cash Ratio or its related term are showing as below:
TSE:7774'
s Cash Ratio Range Over the Past 10 Years
Min: 4.54 Med: 5.95 Max: 8.45
Current: 4.56
During the past 13 years, Japan Tissue Engineering Co's highest Cash Ratio was 8.45. The lowest was 4.54. And the median was 5.95.
TSE:7774's Cash Ratio is ranked better than 62.06% of 1381
companies
in the Biotechnology industry
Industry Median: 2.93
vs TSE:7774: 4.56
Japan Tissue Engineering Co (TSE:7774) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Japan Tissue Engineering Co Cash Ratio Related Terms
Japan Tissue Engineering Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co (TSE:7774) has a Cash Ratio of 5.80 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Japan Tissue Engineering Co and its competitors. This is near median its historical median of 5.95. Over the past decade, Japan Tissue Engineering Co's Cash Ratio has ranged from 4.54 to 8.45. According to the industry distribution chart, Japan Tissue Engineering Co ranks #524 out of 1381 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Japan Tissue Engineering Co's Cash Ratio too high?
Japan Tissue Engineering Co's current Cash Ratio of 5.80 is near median its 10-year median of 5.95. Over the past 10 years, this metric has ranged from a low of 4.54 to a high of 8.45. The Biotechnology industry median Cash Ratio is 2.93. Japan Tissue Engineering Co's value of 5.80 is 98% above this industry median. Based on the distribution chart, Japan Tissue Engineering Co ranks #524 out of 1381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #524 out of 1381 companies for Cash Ratio. This puts Japan Tissue Engineering Co in the upper half of its industry. The industry median Cash Ratio is 2.93. Japan Tissue Engineering Co's value of 5.80 is 98% above this benchmark. Historically, Japan Tissue Engineering Co's own Cash Ratio has ranged from 4.54 to 8.45 over the past decade. While the company's 10-year median is 5.95 vs. the industry median of 2.93, Japan Tissue Engineering Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Japan Tissue Engineering Co's current Cash Ratio of 5.80 is 98% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Cash Ratio is 5.80, which is near median its own 10-year median of 5.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.75, compared to a current price of 円820.00 — trading 62.1% above its estimated fair value. The current Cash Ratio is 5.80, which is near median its 10-year median of 5.95 and 98% above the Biotechnology industry median of 2.93. Japan Tissue Engineering Co's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Cash Ratio is 5.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円820.00 is trading 62.1% above its estimated GF Value™ of 円505.75.
GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.
Key valuation signals for TSE:7774:
Cash Ratio: 5.80 (near median its 10-year median of 5.95)
GF Value™: 円505.75 vs. price of 円820.00 (62.1% above fair value)
Industry Position: 98% above the Biotechnology median (#524 of 1381)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
55GF Score
Get the complete analysis for TSE:7774
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
